Form 4: Myriad Genetics CEO Paul J. Diaz Sells Shares in Multiple Transactions

Paul J. Diaz, President and CEO of Myriad Genetics, sold a significant number of shares of common stock over three days in May 2024.

Summary

• Paul J. Diaz, the President and CEO of Myriad Genetics Inc., reported the sale of common stock in a series of transactions.
• On May 13, 2024, he sold 57,844 shares at a weighted average price of $25.1288.
• On May 14, 2024, he sold 95,000 shares at a weighted average price of $25.2084.
• On May 15, 2024, he sold 75,000 shares at a weighted average price of $25.0722.
• Following these transactions, Diaz still beneficially owns 1,066,166 shares of Myriad Genetics Inc. common stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the CEO selling a significant number of shares, which could raise concerns among investors, although the reasons for the sale are unknown.

Negatives

• The CEO's sale of a significant number of shares could be interpreted negatively by investors.

Risks

• Further sales of shares by the CEO could put downward pressure on the stock price.
• The reasons behind the share sales are not disclosed, creating uncertainty.

Industry Context

Insider selling is a common occurrence, but the market often scrutinizes the timing and volume of such transactions for signals about a company's prospects.

Stakeholder Impact

• Shareholders may react to the CEO's stock sales, potentially impacting the stock price.
• The sales could raise questions among employees about the company's future prospects.

Key Dates